In PD-L1 positive [tumor proportion score (TPS) ≥ 50%] tumors, single-agent immunotherapy, such as pembrolizumab, improves PFS and OS, with 31.9% reaching 5-year survival, compared to 16.3% for chemotherapy [9, 10]. This evidence concerns the gene CD274 and neoplasm.